Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.
In recent years, several beneficial cell samples and microbial strains have been discovered, engineered, and studied, resulting in scientific discoveries and other technological breakthroughs such as vaccines and medicines benefitting communities all around the world. However, several medical products tend to require very low temperatures for storage, making Ultra-Low Freezers increasingly important to maintain their viability.
German Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
Building a sustainable future this is what drives us. We are passionate about making smart biotech materials part of everyday life. We believe nature offers better alternatives to existing materials with biofabricated technologies previously unimaginable – enabling our customers to make a true change.
